Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: A leading developer and manufacturer of life science technologies, products, and services for research, drug discovery, and preclinical testing. The company operates globally with two primary product families: Cellular and Molecular Technologies (CMT) and Preclinical. In January 2026, the company announced "Project Viking," a strategic consolidation of manufacturing operations to improve efficiency.
Key Financial Metrics
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Revenues | $86,550 | $94,135 |
| Gross Profit | $49,910 | $54,766 |
| Gross Margin | 57.7% | 58.2% |
| Operating Loss | $(48,580) | $(6,211) |
| Net Loss | $(56,700) | $(12,405) |
| Loss Per Share (Basic & Diluted) | $(1.28) | $(0.28) |
| Cash and Cash Equivalents | $8,614 | $4,108 |
| Total Debt (Principal) | $40,000 | $37,350 |
| Operating Cash Flow | $6,729 | $1,440 |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 8.1% to $86.6 million, primarily due to softening demand from distributors, CROs, and academic institutions. Foreign currency exchange rates had a favorable effect of $1.2 million.
- Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $47.951 million in Q1 2025 after determining the carrying value of the reporting unit exceeded its fair value by $48.0 million. This was the primary driver of the increased net loss.
- Debt Refinancing: On December 17, 2025, the company completed a comprehensive refinancing of its credit facility (the "2025 Loan Agreement") with BroadOak Income Fund, L.P., replacing the prior facility. This alleviated substantial doubt about the company's ability to continue as a going concern.
- Expense Reductions: Operating expenses decreased significantly due to cost-cutting measures. Sales and marketing expenses dropped 13.5%, General and Administrative expenses dropped 17.5%, and R&D expenses dropped 15.2%.
- Stock Split: On March 13, 2026, the company effected a 1-for-10 reverse stock split to regain compliance with Nasdaq listing requirements.
Guidance, Outlook, and Risks
- Strategic Pillars: Management is focusing on four pillars: leading the translational bridge (organoid/3D biology), expanding the New Product Introduction (NPI) pipeline, shifting revenue mix toward higher-margin consumables (targeting 55% recurring revenue), and achieving operational excellence.
- Project Viking: The company expects to incur pre-tax restructuring charges of $3.4 million to $4.4 million related to the consolidation of manufacturing (closing Holliston, MA; moving to Minneapolis, MN, and Europe). This initiative is expected to yield $3 million in savings in 2027 and $4 million annually starting in 2028.
- Going Concern: While substantial doubt existed in prior quarters due to debt maturity and covenant compliance, the December 2025 refinancing has alleviated these concerns as of the filing date.
- Key Risks:
- Nasdaq Compliance: The company received notice of non-compliance with the minimum bid price requirement, necessitating the reverse stock split. Failure to maintain compliance could lead to delisting.
- Debt Covenants: The new credit agreement includes strict financial covenants, including minimum liquidity and adjusted EBITDA requirements.
- Internal Controls: Material weaknesses in internal controls identified in 2024 (order-to-cash and inventory counts) have been remediated as of December 31, 2025.
- Customer Concentration: No single customer accounted for more than 10% of revenue, but the business is heavily dependent on pharmaceutical/biotech R&D spending and government funding (e.g., NIH).
Investor Verification Checklist
- Debt Service Capacity: Verify the company's ability to meet the high interest rates (approx. 12.8% - 13.7%) and principal amortization requirements of the new 2025 Loan Agreement.
- Project Viking Execution: Monitor the timeline and cost impact of the manufacturing consolidation to ensure projected savings are realized without disrupting supply chains.
- Revenue Recovery: Assess whether the softening demand in the life sciences sector is a temporary cyclical issue or a structural decline affecting the CMT and Preclinical product lines.
- Stock Liquidity: Confirm the trading volume and price stability of the common stock post 1-for-10 reverse split to ensure continued Nasdaq listing compliance.
- Goodwill Valuation: Review the assumptions used in the goodwill impairment test to understand the current fair value of the reporting unit relative to its carrying value.